CYCN
Cyclerion Therapeutics, Inc.
Key Financials
Operating Income
$-4973000
↓ 37.1%
Revenue
$2.1M
↑ 3.7%
EPS (Diluted)
$-1.11
↑ 8.3%
Total Assets
$10.0M
↑ 4.3%
Net Income
$-3528000
↓ 15.4%
Shareholders' Equity
$9.1M
↑ 2.7%
Cash & Equivalents
$3.2M
↑ 0.2%
Operating Cash Flow
$-3314000.00
↑ 23.5%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 425 | 4/1/2026 | View on SEC |
| 8-K | 4/1/2026 | View on SEC |
| 10-K | 3/30/2026 | View on SEC |
| 8-K | 2/17/2026 | View on SEC |
| 8-K | 1/6/2026 | View on SEC |
| 8-K | 12/1/2025 | View on SEC |
| 10-Q | 11/12/2025 | View on SEC |
| 10-K/A | 11/12/2025 | View on SEC |
| SCHEDULE 13G | 10/17/2025 | View on SEC |
| 8-K | 9/23/2025 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | CYCN |
| Company Name | Cyclerion Therapeutics, Inc. |
| CIK | 1755237 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | MA |
| Phone | 617-621-7722 |